Amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis
Conditions
Interventions
Intervention 1: Intervention group: Receiving autologous mesenchymal stem cells from the bone marrow ( 1 million cell/kg BW), along with common treatments (physiotherapy and occupational therapy) alo
Sponsors
Mashhad University of Medical Sciences
Pernia Knowledge-based Company
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Definite Amyotrophic Lateral Sclerosis ( ALS) patients who have been diagnosed with ALS by a specialist neurologist and have The Revised Amyotrophic Lateral Sclerosis Functional Rating Scale-R (ALSFRS-R) of 31 to 46 Patients who have been treated with a define dose of Rilozule for the past three months. Patients who have entered the study by filling the informed consent form. Patients who do not use ventilators Patients who do not have any other chronic diseases that may interfere with the study.
Exclusion criteria
Exclusion criteria: The presence of specific autoimmune and underlying diseases, cancer and any malignancy. Simultaneous participation in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of The Revised Amyotrophic Lateral Sclerosis Functional Rating Scale ( ALSFRS-R). Timepoint: Before the study and 6 months after the intervention. Method of measurement: Using an international standard questionnaire.;Determination of Forced vital capacity (FVC). Timepoint: Before the study and 6 months after the intervention. Method of measurement: Using a spirometry test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Measurement of IL-10, TGF-? and IL-4 cytokines. Timepoint: Before the study and 6 months after the intervention. Method of measurement: Elisa test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Seysd Jalil Tavakol Afshari
Mashhad University of Medical Sciences
Outcome results
None listed